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INTRODUCTION 
 Non motor symptoms(NMS) in Parkinson’s Disease constitutes a 
major clinical challenge, as they are common, yet often overshadowed by 
the dominance of motor symptoms and high awareness of these among 
treating health care professionals. The NMS of PD were recognised by 
James Parkinson himself. Thus in his essay on the shaking Palsy in 1817, 
he referred to sleep disturbances, dysathria, constipation, dysphagia, 
sialorhoea, urinary incontinence, constant sleepiness with slight delirium. 
Since then numerous studies have indicated that NMS are frequent 
accompaniments of PD affecting memory, bladder and bowel and sleep 
among others. These NMS significantly affect the quality of life and may 
precipitate hospitalization. Although common the NMS of PD are not 
well recognised in clinical practice. While some such as depression, 
dementia, autonomic and sleep disturbances are well known, others such 
as dysphagia, dribbling of saliva, weight changes, sexual problems and 
diplopia are less well recognised. 
 The NMS include neuropsychiatric symptoms, sleep disorders,    
autonomic symptoms, sensory symptoms and miscellaneous symptoms 
like diplopia, fatigue and seborhea. The nonmotor symptoms 
questionnaire (NMS Quest) and the nonmotor symprom scale (NMSS) 
were developed to assess the frequency and severity of NMS in PD 
patients across all stages. The NMS Quest was validated in march 2007 
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by the Movement Disorder Society. It covers 9 domains and includes 30 
items, including sleep / fatigue, cardiovascular, mood/cognition, 
perceptual problems, attention / memory, gastrointestinal, urinary, sexual 
functions and miscellaneous. The NMS Quest does not provide an overall 
score or disability and is not a graded rating instrument. It is a screening 
tool designed to draw attention to the presence of NMS and to initiate 
further investigation. 
 Recent studies using the NMS Quest for PD patients have 
highlighted the significant occurrence of a range of different NMS in PD 
patients. Further studies validating the nonmotor symptom scale (NMSS) 
also indicated a strong relationship between the burden of NMS in PD 
and health related quality of life (QOL).The development of tools  such 
as the NMS Quest and NMSS alongside the revamped UPDRS which 
includes a specific nonmotor domain will help define research and 
therapy to improve the recognition and managememt of NMS of PD. 
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AIMS AND OBJECTIVES 
1. To study  the prevalence of nonmotor features across the various 
stages of Idiopathic Parkinson’s Disease and  
2. To correlate it with the severity and duration of the disease. 
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MATERIALS AND METHODS 
 Patients with Idiopathic Parkinson’s Disease who attend the 
Movement Disorder clinic at the Institute of Neurology were studied. A 
detailed and complete neurological examination was done. Imaging, CT 
and MRI brain was done to exclude Parkinson Plus syndromes and 
vascular parkinsonism. The patients were in the age group of more than 
50 years and the disease duration varied between less than 5 years,5 to 10 
years and more than 10 years. The motor symptoms were assessed 
through the Unified Parkinson’s Disease Rating Scale(UPDRS) and the 
disease staged according to the Hoehn and Yahr staging from stage 0 to 
stage 5.The nonmotor features were assessed through the Nonmotor 
Symptoms Questionnaire(NMS QUEST) which contains 30 items. This 
included cognitive dysfunction,sleep disorders,autonomic abnormalities, 
fatigue and depression. The prevalence of these Nonmotor symptoms 
across the various stages of the disease was studied and its correlation 
with the disease severity and duration assessed. 
INCUSION CRITERIA: 
1 Idiopathic Parkinson’s Disease patients with the age of onset of the 
disease at 50 years and above 
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EXCLUSION CRITERIA: 
1. Young onset Parkinson’s Disease(YOPD) with the age of onset 
below 50 years 
2. Parkinson’s Plus Syndromes like Progressive Supranuclear 
Palsy(PSP), Multi System Atropy (MSA), Corticobasal 
Degeneration(CBD) 
3. Patients with Vascular Parkinsonism.  
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REVIEW OF LITERATURE 
 Parkinson’s Disease (also known as Parkinson disease or PD) is a 
degenerative disorder of the central nervous system that often impairs the 
sufferer's motor skills, speech, and other functions. It is characterized by 
muscle rigidity, tremor, a slowing of physical movement (bradykinesia) 
and a loss of physical movement (akinesia) in extreme cases. The primary 
symptoms are the results of decreased stimulation of the motor cortex by 
the basal ganglia, normally caused by the insufficient formation and 
action of dopamine, which is produced in the dopaminergic neurons of 
the brain. Secondary symptoms may include high level cognitive 
dysfunction and subtle language problems. PD is both chronic and 
progressive. PD is the most common cause of chronic progressive 
parkinsonism, a term which refers to the syndrome of tremor, rigidity, 
bradykinesia and postural instability. PD is also called "primary 
parkinsonism" or "idiopathic PD". While many forms of parkinsonism are 
"idiopathic", "secondary" cases may result from toxicity most notably of 
drugs, head trauma, or other medical disorders. The disease is named 
after English apothecary James Parkinson, who made a detailed 
description of the disease in his essay: "An Essay on the Shaking Palsy" 
(1817). 
 The term Parkinsonism is used for symptoms of tremor, stiffness, 
and slowing of movement caused by loss of dopamine. "Parkinson's 
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disease" is the synonym of "primary parkinsonism", i.e., isolated 
parkinsonism due to a neurodegenerative process without any secondary 
systemic cause. In some cases, it would be inaccurate to say that the 
cause is "unknown", because a small proportion is caused by genetic 
mutation. 
ETIOLOGY:               
 Most people with Parkinson's disease are described as having 
idiopathic Parkinson's disease. There are far less common causes of 
Parkinson's disease including genetic, toxins, head trauma, cerebral 
anoxia, and drug-induced Parkinson's disease.                                                                    
 Genetic; Someone who has Parkinson's disease is more likely to 
have relatives that also have Parkinson's disease. However, the 
inheritance of Parkinson's disease is usually complex and not due to a 
single gene defect. A number of specific genetic mutations causing 
Parkinson's disease have been discovered. Genes identified as of 2008 are 
Alpha-synuclein (SNCA), ubiquitin carboxy-terminal hydrolase L1 
(UCH-L1), parkin (PRKN), leucine-rich repeat kinase 2 (LRRK2 or 
dardarin) , PINK 1 and DJ-1.With the exception of LRRK2 they account 
for a small minority of cases of PD. 
 Toxins; One theory holds that many or even most cases of the 
disease may result from the combination of a genetically determined 
vulnerability to environmental toxins along with exposure to those toxins. 
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The toxins most strongly suspected at present are certain pesticides and 
transition-series metals such as manganese or iron, especially those that 
generate reactive oxygen species, and/or bind to neuromelanin.In a 
longitudinal investigation, individuals who were exposed to pesticides 
had a 70% higher incidence of PD than individuals who were not 
exposed. 
 Head trauma; Head trauma is considered a risk factor for PD since 
past episodes are reported more frequently by individuals with 
Parkinson's disease than by others in the population.  
PATHOPHYSIOLOGY: 
 
 Dopaminergic pathways of the human brain in normal condition 
(left) and Parkinson's disease (right). Red Arrows indicate suppression of 
the target, blue arrows indicate stimulation of target structure. 
 The symptoms of Parkinson's disease result from the greatly 
reduced activity of pigmented dopamine-secreting (dopaminergic) cells in 
the pars compacta region of the substantia nigra. These neurons project to 
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the striatum and their loss leads to alterations in the activity of the neural 
circuits within the basal ganglia that regulate movement, in essence an 
inhibition of the direct pathway and excitation of the indirect pathway. 
The direct pathway facilitates movement and the indirect pathway 
inhibits movement, thus the loss of these cells leads to a hypokinetic 
movement disorder. The lack of dopamine results in increased inhibition 
of the ventral anterior nucleus of the thalamus, which sends excitatory 
projections to the motor cortex, thus leading to hypokinesia.There are 
four major dopamine pathways in the brain; the nigrostriatal pathway, 
referred to above, mediates movement and is the most conspicuously 
affected in early Parkinson's disease. The other pathways are the 
mesocortical, the mesolimbic, and the tuberoinfundibular. Disruption of 
dopamine along the non-striatal pathways likely explains much of the 
neuropsychiatric pathology associated with Parkinson's disease. 
 The mechanism by which the brain cells in Parkinson's are lost 
may consist of an abnormal accumulation of the protein alpha-synuclein 
bound to ubiquitin in the damaged cells. The alpha-synuclein-ubiquitin 
complex cannot be directed to the proteasome. This protein accumulation 
forms proteinaceous cytoplasmic inclusions called Lewy bodies. The 
latest research on pathogenesis of disease has shown that the death of 
dopaminergic neurons by alpha-synuclein is due to a defect in the 
machinery that transports proteins between two major cellular organelles 
— the endoplasmic reticulum (ER) and the Golgi apparatus. 
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Excessive accumulations of iron, which are toxic to nerve cells, are also 
typically observed in conjunction with the protein inclusions. Iron and 
other transition metals such as copper bind to neuromelanin in the 
affected neurons of the substantia nigra. Neuromelanin may be acting as a 
protective agent. The most likely mechanism is generation of reactive 
oxygen species. Iron also induces aggregation of synuclein by oxidative 
mechanisms.Similarly, dopamine and the byproducts of dopamine 
production enhance alpha-synuclein aggregation. The precise mechanism 
whereby such aggregates of alpha-synuclein damage the cells is not 
known. 
CLINICAL FEATURES: 
 MOTOR; Four symptoms are considered cardinal in PD: tremor, 
rigidity, bradykinesia and postural instability. 
 Tremor; normally has a frequency between 4 and 6 Hz (cycles per 
second) and is the most apparent and well-known symptom. It is most 
commonly a rest tremor, maximal when the limb is at rest and 
disappearing with voluntary movement and sleep. It is a pronation-
supination tremor that is described as "pill-rolling". Tremor affects to a 
greater extent the most distal part of the extremity and is typically 
unilateral at onset. Though around 30% of PD sufferers do not have 
tremor at disease onset most of them would develop it along the course of 
the disease. 
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Rigidity: defined as joint stiffness and increased muscle tone. In 
combination with a resting tremor, this produces a ratchety, "cogwheel 
rigidity" when the limb is passively moved. It may be associated with 
joint pain, such pain being a frequent initial manifestation of the disease. 
 Bradykinesia and Akinesia: the former refers to slowness of 
movement while the latter to the absence of it. It is the most characteristic 
clinical feature of PD and it produces difficulties not only with the 
execution of a movement but also with its planning and initiation. The 
performance of sequential and simultaneous movements is also hindered. 
Rapid, repetitive movements produce a dysrhythmic and decremental loss 
of amplitude. 
 Postural Instability: failure of postural reflexes, along other disease 
related factors such as orthostatic hypotension or cognitive and sensory 
changes, which lead to impaired balance and falls.It usually appears in 
the late stages of PD. 
Other motor symptoms include: 
 Gait and posture disturbances: Shuffling gait: gait is characterized 
by short steps, with feet barely leaving the ground. Small obstacles tend 
to cause the patient to trip. Decreased arm-swing. 
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 Turning "en bloc": rather than the usual twisting of the neck and 
trunk and pivoting on the toes, PD patients keep their neck and trunk 
rigid, requiring multiple small steps to accomplish a turn. 
 Camptocormia: stooped, forward-flexed posture. In severe forms, 
the head and upper shoulders may be bent at a right angle relative to the 
trunk. 
 Festination: a combination of stooped posture, imbalance, and 
short steps. It leads to a gait that gets progressively faster and faster, often 
ending in a fall. 
 Gait freezing: also called motor blocks, is a manifestation of 
akinesia. Gait freezing is characterized by a sudden inability to move the 
lower extremities which usually lasts less than 10 seconds. It may worsen 
in tight, cluttered spaces, when attempting to initiate gait or turning 
around, or when approaching a destination. Freezing improves with 
treatment and also with behavioral techniques such as marching to 
command or following a given rhythm. 
 Dystonia: abnormal, sustained, painful twisting muscle 
contractions, often affecting the foot and ankle (mainly toe flexion and 
foot inversion) which often interferes with gait. 
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 Speech and swallowing disturbances;  Hypophonia: soft speech. 
Monotonic speech: Speech quality tends to be soft, hoarse, and 
monotonous. Festinating speech: excessively rapid, soft, poorly-
intelligible speech. Drooling: most likely caused by a weak, infrequent 
swallow. Dysphagia; paired ability to swallow; which in the case of PD is 
probably related to an inability to initiate the swallowing reflex or by a 
too long laryngeal or oesophageal movement. Can lead to aspiration 
pneumonia. 
 Other motor symptoms: Fatigue, Hypomimia:a mask-like face, 
Difficulty rolling in bed or rising from a seated position. Micrographia: 
small, cramped handwriting. Impaired fine motor dexterity and motor 
coordination. Impaired gross motor coordination. Akathisia: an 
unpleasant desire to move. Reemergence of primitive reflexes. 
NONMOTOR SYMPTOMS: 
 Neuropsychiatric symptoms; Depression, apathy, anxiety, panic 
attacks, anhedonia, attention deficit. hallucination, illusion, delusion 
(disease or drug induced). Dementia, confusion or delirium (disease 
and/or drug induced). obsessional and impulsive behaviour(usually drug 
induced), repetitive behaviour (punding). 
 Sleep Disorders: Restless legs, Periodic Limb Movements, REM 
behaviour disorder excessive daytime somnolence. Non REM sleep 
related Disorder, vivid dreaming, insomnia. 
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 Autonomic symptoms; Bladder disturbances; urgency, nocturia, 
frequency, hyperhidrosis orthostatic hypotension; Vcoat hanger pain. 
Sexual dysfunction; hypersexuality, erectile dysfunction, loss of libido. 
Dry eyes (xerophthalmia) or wet eyes (lacrimation), dry mouth 
(xerostomia), dribbling of saliva (sialorrhoea). 
 Gastrointestinal symptoms;(overlap with autonomic)include 
delayed gastric emptying, ageusia, dysphagia, choking, reflux. vomiting, 
nausea (usually drug related), constipation, anismus, volvulus, 
megacolon. incomplete voiding of bowel, faecal incontinence. 
 Sensory symptoms; are pains, paraesthesia, olfactory  disturbance 
(hyposmia). 
 Miscellaneous symptoms; like fatigue, diplopia, blurred vision, 
seborrhoea, weight loss. 
 Fluctuation related NMS; include pain, mental clouding, anxiety, 
panic attacks, depression, hallucination, psychosis, screaming, 
hyperventilation, hypoventilation. Hyperhidrosis, temperature changes, 
somnolence, restless legs, akathisia. Belching, dysphagia, constipation, 
anismus, urinary voiding difficulty, altered blood pressure. 
 A common misconception is that NMS occur only in late or 
advanced PD. However NMS can first present at any stage of the disease. 
Several NMS of PD such as olfactory dysfunction, constipation, 
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depression  and erectile dysfunction may predate the motor signs, 
symptoms and diagnosis of PD by a number of years.NMS may appear 
early in the course of PD and become prominent as the disease 
progresses, often dominating the later stages of the diseases. It is likely 
that some NMS such as olfactory dysfunction in combination with other 
symptoms such as REM behavioural disorder or constipation may form 
part of a battery of tests to identify a population at risk of PD, which will 
be particularly important if and when neuroprotective therapies become 
available. 
 Stacy et al found that NMS were common even in patients within 5 
years of (motor)disease arrest and they were captured much more 
frequently with the use of a patient completed Questionnaire (NMS 
QUEST)than simply in the course of a routine clinic appraisal, including 
the questions in the Unified Disease Rating Scale(UPDRS). Recent 
studies using the nonmotor symptoms questionnaire for PD (NMS Quest) 
have highlighted the significant occurrence of a range of 30 different 
NMS in PD in comparison with an age matched control group. These 
occurred across a range of PD patients from early to advanced disease, 
correlating strongly with advancing disease. In particular many NMS 
such as dribbling saliva, dysphagia, sexual problems and pain had not 
been discussed with the doctor before being flagged up by the NMS 
Quest. The study also highlighted that, irrespective of county of study and 
disease stage, most PD patients are likely to flag up 9 to 12 different 
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NMS in the NMS Quest at clinic visit. Additionally, further studies 
validating the first dedicated scale for NMS of PD, the Parkinson’s 
Disease Nonmotor Scale(NMSS)also indicated a strong relationship 
between the burden of NMS in PD and health related QoL. 
 Most NMS are thought to be refractory to current dopaminergic 
treatment, although this has not been assessed and this view is 
increasingly challenged. For example, some dopaminergic agonists have 
been reported to improve depression, REM behaviour and nocturia and 
apomorphine may help erectlie dysfunction and anismus in PD. 
Dopominergic agents can alleviate the ‘off’ period related NMS of PD, 
such as pain, anxiety and depressed mood. In particular the rapid and 
reliable onset of action of apomorphine injection or booster can transfer 
the lives of subjects whose off NMS dominate their lives. 
 However many NMS may need specific targeted non-dopaminergic 
treatment and the development of successful therapies for NMS will 
depend upon accurate reproducible and robust means of quantification, an 
understanding of their prevalence and evolution with disease progression 
and their effect on QoL. 
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DIAGNOSIS: 
 The diagnosis is based on medical history and neurological 
examination conducted by interviewing and observing the patient in 
person using the Unified Parkinson's Disease Rating Scale.  
 The UPDRS is a scale that was developed as an effort to 
incorporate elements from existing scales to provide a comprehensive but 
efficient and flexible means to monitor PD-related disability and 
impairment. The scale itself has four components, largely derived from 
preexisting scales that were reviewed and modified by a consortium of 
movement disorders specialists (Part I, Mentation, Behavior and Mood; 
Part II, Activities of Daily Living; Part III, Motor; Part IV, 
Complications).The UPDRS is often accompanied by and reported with 
such scales as the Schwab and England and Hoehn and Yahr scales, these 
latter scales are not part of the UPDRS per se. The strengths of the 
UPDRS are many, and the scale provides a relatively comprehensive 
assessment of motor aspects of PD. Extensive clinimetric analyses have 
already been conducted on the UPDRS, providing it both scientific and 
clinical credibility. The UPDRS is less comprehensive in its assessment 
of nonmotor features of the disease. 
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HOEHN and YAHR STAGE: 
STAGE  O-    No signs of disease 
1-   Unilateral disease 
1.5-  Unilateral plus axial involvement 
2.0- Bilateral disease, without impairment of balance 
2.5- Mild bilateral disease, with recovery on pull test 
3.0- Mild to moderate bilateral disease, some postural 
 instability, physically independent 
4.0- Severe disability, still able to walk or stand unassisted 
5.0- Wheelchair bound or bedridden unless aided  
IMAGING: 
 SPECT,  FDGPET and fMRI scans are used for diagnosing 
Parkinson's Disease. Due to this, the disease can be difficult to diagnose 
accurately, especially in its early stages. Due to symptom overlap with 
other diseases, only 75% of clinical diagnoses of PD are confirmed to be 
idiopathic PD at autopsy. Early signs and symptoms of PD may 
sometimes be dismissed as the effects of normal aging. The physician 
may need to observe the person for some time until it is apparent that the 
symptoms are consistently present. However, CT and MRI brain scans of 
people with PD usually are normal. 
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TREATMENT: 
 Parkinson's disease is a chronic disorder that requires broad-based 
management including patient and family education, support group 
services, general wellness maintenance, physiotherapy, exercise, and 
nutrition. At present, there is no cure for PD, but medications or surgery 
can provide relief from the symptoms. 
 LEVODOPA: Levodopa remains the most effective medication to 
improve motor features of PD with the fewest short-term side effects. It 
effectively ameliorates bradykinesia and rigidity but is variably effective 
for tremor. Levodopa is combined with the peripheral dopa decarboxylase 
inhibitor carbidopa to reduce the peripheral metabolism of levodopa to 
dopamine. This reduces nausea and increases levodopa delivery to the 
brain, where it is converted to dopamine, stored, and slowly released by 
remaining dopaminergic neurons. 
  Carbidopa / levodopa, now available generically, is available as 
immediate release ([IR] 10/100, 25/100, and 25/250)and controlled 
release ([CR] 25/100 and 50/200) formulations. Carbidopa / levodopa IR 
and CR are also available as generics. The initial target dose is typically 
carbidopa / levodopa IR 25/100administered 3 or 4 times per day, or 
carbidopa / levodopa CR 50/200 twice a day, although these are more a 
matter of convention than scientific rigor. Starting carbidopa / levodopa 
at a dosage of one-half tablet once a day and increasing the daily dose by 
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one-half tablet every week until the target dose is reached may be helpful 
to avoid nausea. Although carbidopa / levodopa is usually administered 
away from meals to achieve the most rapid onset of action and the most 
reliable effect, if nausea does occur, it can often be reduced by having 
patients take the dose immediately following a meal. Levodopa alone has 
a half-life of approximately 60 minutes, and when given with carbidopa it 
has a half-life of approximately 90 minutes. 
 As the disease progresses and more dopamine neurons are lost, the 
duration of clinical benefit shortens to a few hours, and many patients 
develop choreiform (twisting, turning) movements when levodopa-
derived dopamine in the brain is peaking (peak dose dyskinesias). The 
use of carbidopa / levodopa CR in early disease may be more convenient 
and require fewer daily doses, but it has not been found to reduce the 
development of motor fluctuations and dyskinesia compared with 
carbidopa/levodopa IR. 
 Parcopa is an orally disintegrating carbidopa / levodopa tablet that 
dissolves within seconds after being placed on the tongue. Parcopa is 
convenient for patients because it can be taken with or without water, 
such as when traveling, and is especially helpful for patients who have 
swallowing problems. After dissolving, Parcopa is carried in the saliva to 
the proximal small bowel where it is absorbed. Three strengths of 
Parcopa are available: carbidopa / levodopa 10/100, 25/100, and 25/250. 
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Parcopa was approved based on the demonstration of bioequivalence with 
Sinemet IR and should provide the same clinical benefit and side effects. 
 COMT INHIBITORS: Levodopa is also metabolized peripherally 
by catechol-O-methyltransferase(COMT) to produce 3-O-methyldopa 
(3-OMD). Entacapone is a selective, reversible, peripherally acting 
COMT inhibitor that is used in conjunction with carbidopa/levodopa to 
extend the levodopa half-life and allow more levodopa to be delivered to 
the brain over a longer time. Entacapone is approved as an adjunct to 
carbidopa/levodopa in patients who experience end-of-dose wearing off. 
Entacapone is customarily administered with each dose of 
carbidopa/levodopa. Some patients will notice an orange or brown 
discoloration of urine, saliva, or sweat.Diarrhea occurs in 4% to 10% of 
patients treated with entacapone. Hepatotoxicity has not been found to 
occur with entacapone use, and routine liver monitoring is unnecessary. 
 Stalevo is a combination of carbidopa, levodopa, and entacapone. 
Stalevo provides a convenient option for patients who are taking 
carbidopa / levodopa and entacapone tablets and may be easier to 
swallow. Stalevo is recommended for use in patients who have end-of-
dose wearing off on carbidopa/levodopa IR . In these patients, switching 
from carbidopa / levodopa to Stalevo is comparable to adding entacapone 
but with a reduced pill burden. For patients with dyskinesia and those 
taking greater than 600-mg levodopa per day it is recommended that 
entacapone should first be added, and if dyskinesia increases, the 
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levodopa dosage can be reduced. Once stabilized on carbidopa / levodopa 
plus entacapone, the patient can be switched to the comparable dose 
Stalevo tablets. 
 Tolcapone is a selective, centrally and peripherally acting, 
reversible COMT inhibitor that is used to reduce off time in patients with 
motor fluctuations on carbidopa / levodopa. Tolcapone extends the 
levodopa half-life more than entacapone, but because of the potentially 
fatal side effect of hepatic failure, its use is reserved for patients who 
cannot be adequately controlled with other PD medications. It is 
recommended that patients provide written informed consent before the 
medication is begun, and liver function tests should be monitored for at 
least 6 months. The new recommendations indicate that liver function 
tests (serum alanine aminotransferase and aspartate aminotransferase) 
should be performed every 2 to 4 weeks during the first 6 months of 
therapy and then periodically according to the clinical judgement of the 
health care provider. 
 Patients should discontinue tolcapone if liver enzyme levels exceed 
twice the upper limit of normal. The usual initial dosage is 100 mg 3 
times a day (tid), and it can be increased to 200 mg tid if necessary. 
Tolcapone should be discontinued if benefit is not observed.Controlled 
trials indicate that tolcapone improves motor function while allowing 
reductions in levodopa dosage. One study that evaluated the use of 
tolcapone in PD patients with motor fluctuations found a daily reduction 
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in off time of 2.0 hours in patients taking 100 mg tid and 2.5 hours in 
patients taking 200 mg tid compared with baseline. In comparison, 
patients taking placebo had only a 0.3-hour reduction in daily off time.  
 The levodopa boosting effects of the addition of tolcapone are 
usually evident the day it is added. The main side effect is an increase in 
dyskinesia. This occurs to a greater extent with tolcapone than with 
entacapone, and in patients with dyskinesias it is often helpful to reduce 
the levodopa dose by 25% to 50% when tolcapone is added. Other 
potential side effects include diarrhea in 10% of patients. The diarrhea 
can be severe and is usually delayed for 4 to 12 weeks after initiation of 
therapy and uncommon after 6 months. 
 DOPAMINE AGONISTS : DAs are effective as monotherapy in 
early PD to improve motor symptoms and as adjuncts to levodopa in 
patients with motor fluctuations to reduce off time. They directly 
stimulate dopamine receptors in the striatum, have relatively long half-
lives and are less likely to cause motor complications than levodopa. The 
oral DAs are less effective than levodopa as the disease progresses but 
often provide adequate benefit as monotherapy for 1 to 3 years. 
Additional potential side effects include sleepiness, hallucinations, 
peripheral edema, hypersexuality, and pathological gambling. 
Hallucinations generally occur in patients with underlying dementia. 
Multiple clinical trials have demonstrated that initial treatment with a DA 
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to which levodopa can be added causes fewer motor fluctuations and 
dyskinesia than treatment with levodopa alone. 
 Pramipexole is a nonergot D2/D3 synthetic aminobenzothiazole 
derivative that is effective as monotherapy in early disease and as an 
adjunct to levodopa in patients with motor fluctuations. In the 
Comparison of the Agonist Pramipexole to Levodopa Regarding 
Emergence of Motor Fluctuations in PD (CALM-PD) study, 301 patients 
were randomized to receive initial treatment with pramipexole or 
levodopa and were followed for 4 years. Open-label levodopa could be 
added as necessary. At study endpoint, patients assigned to levodopa had 
better motor function than those taking pramipexole. However, only25% 
of patients initially treated with pramipexole exhibited dyskinesia 
compared with 54% of patients initially treated with levodopa.  
 The usual maximum dose of pramipexole is 4.5 mg/d in three 
divided doses. It is started at a dosage of 0.125 mg tid for a week and then 
titrated to 0.5 mg tid. Further escalation can be undertaken as necessary. 
Side effects include somnolence, hallucinations, cognitive dysfunction, 
and edema. Recent reports indicate that pathological gambling may be 
associated with DAs, especially pramipexole, usually at high doses. In 
one review, the incidence of pathological gambling was 1.5% in patients 
taking pramipexole (mean dosage 4.3 mg/d, range 2 mg/d to 8 mg/d), 
compared with an overall incidence of 0.05% in patients with PD 
regardless of therapy. Excessive shopping and hypersexuality are other 
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forms of impulse control disorders that may occur with DA use. Patients 
should be warned about these behaviours when DAs are prescribed, and 
DA dosages may need to be reduced, if these problems emerge. 
 Ropinirole  is a non ergot DA with a strong affinity for D2 
receptors. It is effective as monotherapy in early disease and as an adjunct 
to levodopa in patients with motor fluctuations. One study of ropinirole as 
monotherapy in patients with early PD found a 24% improvement in 
motor function in patients taking ropinirole  after 6 months compared 
with a 3% worsening for those patients taking placebo. Ropinirole has 
also been shown to reduce the development of dyskinesia in early PD 
patients compared with treatment with levodopa. A 5-year study that 
randomized patients to initial treatment with ropinirole or levodopa to 
which levodopa could be added when necessary found that only 20% of 
patients assigned to ropinirole developed dyskinesia, compared with 45% 
of patients assigned to levodopa. 
 These findings indicate that initial dopaminergic treatment with 
ropinirole leads to a lower incidence of dyskinesia, and levodopa can be 
added when necessary to control motor symptoms as the disease 
progresses. The recommended initial dosage for ropinirole is 0.25 mg 3 
times daily (total 0.75 mg per day). This can be increased weekly by  
0.25-mg increments at each dose. The daily dose can then be increased by 
1.5 mg/d after week 4 on a weekly basis up to a dose of 9 mg/d, and then 
by up to 3 mg/d weekly up to the recommended maximum total daily 
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dose of 24 mg/d. Side effects include somnolence, hallucinations, 
peripheral edema, and rarely impulse control disorders. 
 Pergolide, an ergot DA with strong affinity for D2 receptors, is 
effective in reducing motor symptoms in PD. Several studies have shown 
that the use of pergolide permits a significant reduction in levodopa 
dosage when it is used as adjunct therapy in patients with motor 
fluctuations compared with placebo. 
 Pergolide is usually initiated at a dose of 0.05 mg for the first 2 
days and increased by 0.1 mg/d or 0.15 mg/d every third day over the 
next 12 days. Pergolide may then be increased by 0.25 mg/d every third 
day until an optimal therapeutic dose is achieved. Pergolide is usually 
aministered in divided doses 3 times per day, and the usual maximum 
dosage is 3 mg/d to 4 mg/d. Studies have identified an increased 
frequency of valvular heart disease in patients taking pergolide. This 
appears to be a potential side effect of all ergot agonists, and the 
mechanism is believed to be activation of 5-hydroxytryptamine 2B  
(5-HT2B) receptors. It may therefore be appropriate to obtain early 
echocardiograms on patients who are receiving pergolide. 
Pleuropulmonary and retroperitoneal fibrosis can also rarely occur. 
 Apomorphine is a nonergot DA that is approved as a subcutaneous 
injection to treat acute intermittent off and hypomobility states in PD as a 
rescue medication. Originally introduced as a PD drug in the mid-20th 
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century, its use was initially limited by side effects, including marked 
nausea. It is now administered with an antiemetic. When injected 
subcutaneously, its onset of action is approximately 10 to 15 minutes with 
the effect lasting from 90 to 120 minutes. Side effects of apomorphine 
include nausea, somnolence, dyskinesia, vomiting, and yawning. 
 The appropriate dosage for each patient must be determined based 
on clinical response and side effects. Advanced patients who are 
considering apomorphine should be pretreated with the antiemetic 
trimetho benzamide 300 mg tid orally for atleast 3 days. Patients then 
visit the doctor’s office in the off state and receive a test dose of 
apomorphine 2 mg  subcutaneously. Orthostatic blood pressures are 
measured at 20, 40, and 60 minutes following the first test dose. If the  
2-mg dose reverses PD symptoms, this dose is prescribed. If no clinical 
response occurs, a dose of 4 mg is administered 2 hours after the first 
dose. If the patient experiences a good clinical response, he or she maybe 
treated with a dose of 3 mg per injection and may increase this dosage by 
1mg increments every few days as needed. Most patients respond to 3 mg 
to 6 mg of apomorphine. 
 MAO-B INHIBITORS; Selegiline  is a relatively selective, 
irreversible monoamine oxidase type B (MAO-B) inhibitor that is 
beneficial as an adjunct to levodopa for patients who have motor 
fluctuations. It also has modest symptomatic benefit as monotherapy in 
early PD and has generated interest in possible neuroprotective effects. 
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The Deprenyl and Tocopherol AntioxidativeTherapy of Parkinsonism. 
(DATATOP) study demonstrated that selegiline monotherapy in early 
disease provides modest symptomatic benefit and significantly delays the 
need for levodopa. Oral selegiline is approved as an adjunct to levodopa 
in patients who demonstrate a deteriorating response to treatment.  
 The recommended dosing is 5 mg with breakfast and lunch. Doses 
later in the day may cause insomnia. At dosages above 10 mg/d, oral 
selegiline begins to lose its specificity for MAO-B and should therefore 
usually be avoided because of the risk of tyramine induced hypertensive 
crisis. Selegiline is used with caution with selective serotonin reuptake 
inhibitor(SSRI) antidepressants to avoid the serotonin syndrome 
characterized by agitation, restlessness, rigidity, hyperreflexia, shivering, 
autonomic instability,flushing, fever, nausea, diarrhea, diaphoresis, 
myoclonus, coma, and rarely rhabdomyolysis and death. The Zydis 
selegiline formulation is a wafer that dissolves and is absorbed in the 
mouth, thereby bypassing hepatic first-pass metabolism. This method of 
absorption may allow for higher plasma concentrations of selegiline 
compared with oral selegiline before MAO-A in the gut is inhibited. 
 Rasagiline is an irreversible  MAO-B inhibitor that has been shown 
to effectively treat symptoms of PD when used as monotherapy in 
patients with early PD and as an adjunct to levodopa in patients with 
motor fluctuations. It appears to have greater symptomatic efficacy than 
oral selegiline. Rasagiline provides neuroprotection in a number of cell 
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and animal models and is free of amphetamine metabolites, which have 
been demonstrated to interfere with neuroprotective effects of selegiline. 
 Rasagiline was evaluated as monotherapy in early disease in the 
Rasagiline Mesylate (TVP-1012) in Early Monotherapy for PD Out 
patients (TEMPO) study. Results from the 6-month double-blind phase 
demonstrated that rasagiline significantly improves Unified Parkinson 
Disease Rating Scale (UPDRS) scores compared with placebo and that 
side effects were similar to placebo. The trial also incorporated a  
delayed-start component, and patients who initially received placebo for 
the first 6 months were treated with rasagiline 2 mg/d for the next 6 
months while rasagiline treated patients continued on it. After 1 year, 
patients treated with rasagiline from the beginning of the study had less 
worsening in total UPDRS scores compared with patients who started 
rasagiline after 6 months of placebo. This result suggests that rasagiline 
might have benefit in slowing disease progression,but further 
investigation is needed. 
 Another trial, Parkinson’s Rasagiline: Efficacyand Safety in the 
Treatment of off (PRESTO), evaluated the effect of rasagiline as adjunct 
therapy in levodopa treated patients with motor fluctuations. Another 
study found that both rasagiline once daily and entacapone administered 
with each levodopa dose significantly decreased off time and increased 
on time compared with placebo. Although no dietary restrictions were 
included in the pivotal clinical trials, the USFDA has recommended that 
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patients on rasagiline avoid foods that are high in tyramine, such as 
redwine, aged cheeses, and aged meats. 
 ANTICHOLINERGIC MEDICATIONS:Anticholinergic medica-
tions  such as trihexyphenidyl and benztropine are effective for reducing 
tremor in some patients but have little effect on bradykinesia and rigidity. 
Their use is limited by side effects,  including confusion, 
hallucinations,dry mouth and eyes, urinary retention, ocular 
accommodation abnormalities, sweating, and tachycardia. These drugs 
must be used with caution in older adults and in patients with glaucoma. 
 AMANTIDINE : is an antiviral medication that provides mild 
benefit in treating PD signs and symptoms. It also symptomatically 
reduces levodopa-induced peak-dose dyskinesia. It may act by direct 
stimulation of dopamine receptors and by inhibiting dopamine reuptake. 
Amantadine is administered at a dose of 100 mg bid or tid. It should be 
used cautiously in elderly patients and in those with dementia, as it can 
cause or worsen hallucinations. 
SURGERY AND DEEP BRAIN STIMULATION:  
 After decades of lesion therapy, it was discovered that chronic 
electrical stimulation had significant and lasting benefits for the treatment 
of movement disorders. Deep brain stimulation (DBS) was introduced in 
1987 by Benabid and colleagues for the treatment of tremor in patients 
with Parkinson’s disease (PD). A few short years after its introduction, 
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high-frequency stimulation (HFS) of the globus pallidus interna (GPi), 
and later the subthalamic nucleus (STN), was noted to dramatically 
improve the symptoms of idiopathic PD. DBS is now US Food and Drug 
Administration (USFDA)-approved for the treatment of  PD. The 
treatment is now considered standard of care for a subset of medically 
refractory patients with PD. DBS is often compared with brain lesioning 
(pallidotomy, thalamotomy, subthalamotomy). The main advantages of 
DBS over lesioning include reversibility of the procedure, the ability to 
program the stimulator, and the ability to perform bilateral procedures 
without inducing pseudobulbar and other deficits. 
 Currently STN and GPi are the preferred brain targets for the 
treatment of medication-refractory PD. While each has advantages, 
particularly in the treatment of specific symptoms, there remains no 
consensus as to which target is superior. Both have the potential to 
improve the cardinal features of PD, including tremor, bradykinesia, 
rigidity, gait dysfunction, and postural instability. Additionally, both are 
known to reduce on–off fluctuations, dyskinesias, and dystonia. While 
some studies have concluded that STN DBS was slightly superior in 
improving motor scores, tremor, and bradykinesia, others have not shown 
significant differences. 
 The marked clinical improvement usually seen with bilateral STN 
stimulation. Bilateral STN stimulation does seem to have an advantage 
over GPi in allowing medication reduction, which can also indirectly 
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result in a long-term cost savings. Because of its smaller size, STN has on 
average a lower voltage requirement, which may provide an advantage in 
terms of improving battery life. Dyskinesia management, however, may 
be slightly superior with GPi stimulation, which provides a more direct 
anti dyskinetic effect. 
 Additionally, many mood and cognitive side effects have been 
reported with STN DBS, and their presence has raised questions 
regarding safety in individual patients, particularly elderly persons and 
those with cognitive impairment. To date, no head-to-head trials on which 
to base selection of target have been done. Both targets are USFDA 
approved, and both are efficacious. 
 The thalamic target (ventralis intermedius nucleus or VIM) has 
been found to be efficacious in alleviating PD tremor but has not been 
effective in treating other PD symptoms, including bradykinesia, rigidity, 
dyskinesias, and postural instability. VIM nucleus DBS has been 
demonstrated to be superior inefficacy in improving activities of daily 
living in comparison with unilateral thalamotomy for PD tremor, 
although there may be reasons to opt for lesion therapy. Stimulation of 
the thalamus has also been reported to result in delayed tremor rebound. 
Long-lasting effect on tremor in PD with VIM nucleus DBS has been 
demonstrated however, the lack of effect on other PD symptoms has 
greatly curbed the use of this target for PD. Recent reports suggest the 
paramedian pontine nucleus as a possible target for improvement of gait 
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in parkinsonian patients. If it can be shown that this target improves 
levodopa-unresponsive gait symptoms, it may prove an important 
consideration for future trials. 
 DBS has proven efficacy in the treatment of the major motor 
symptoms of PD, including bradykinesia, rigidity, tremor, gait 
dysfunction, and postural instability. Long-term studies have 
demonstrated that the effects of DBS are sustained. Perhaps the most 
important point to remember when considering the referral of a patient is 
that only those symptoms that respond to levodopa(when the patient is in 
the best optimized on state) will respond to DBS. The main exception to 
this rule is medication-refractory tremor, which can be well controlled 
with DBS. No consensus has been formed as to the appropriate timing for 
DBS surgery, but, in general, the procedure should be reserved for 
medication-responsive symptoms in non demented patients with PD, who 
may also have tremor or on–off fluctuations. In practical terms, the 
patient under consideration for a surgical referral should experience one 
or several of the following difficulties:           
 Motor fluctuations are seen in advanced PD, usually following 5 
years or more of dopaminergic therapy. Many types of fluctuations have 
been described.  The most common and the earliest to appear are wearing 
off of medication doses (predictable worsening of the parkinsonism or 
reaching the off state because the current dose‘ ‘wears off’’ prior to the 
next scheduled dose of levodopa). As the disease progresses, these off 
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states may become more unpredictable, and doses may last for shorter 
intervals. Patients may also experience delayed ons (the period between 
ingesting the dose of levodopa and the appearance of its positive effects), 
dose failures (when a dose of levodopa fails to produce any effect),  
on–off state(fluctuating between the on and off states), or sudden offs (an 
unpredictable off state that may be unrelated to the timing of the levodopa 
dose). A 5-year follow-up study of DBS has shown significant 
improvement in off-medication motor scores. Patients report a significant 
portion of the waking day in an  off-medication state. 
 Dyskinesias become disabling and limit levodopa dosage. DBS can 
decrease the severity of disability related to dyskinesias. Quality of life is 
severely affected as a result of PD, and patients have levodopa - 
responsive symptoms. Quality of life scores have shown an improvement 
with DBS in many studies. The disease itself might not be advanced, but 
if the patient has disabling medication-refractory tremor (dopamine 
agonists, anticholinergics, and combinations have been tried) affecting 
activities of daily living, DBS may be indicated.  
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TREATMENT OF NONMOTOR SYMPTOMS: 
 SLEEP DISORDERS: Excessive daytime sleepiness; (EDS) 
commonly occurs in PD and frequently adversely affects quality of 
life.EDS can be caused by the disease itself, medications, or sleep 
disorders. Predictors of EDS in PD include increasing age, advanced 
disease, and higher dosages of dopaminergic medications. DAs in 
particular are a common cause of EDS in patients with PD. Acareful 
medication review and sleep history are warranted for patients with EDS. 
If a medication that might be causing EDS is identified, it can be reduced 
or discontinued as feasible. If no medication likely to cause sleepiness is 
identified, if EDS persists despite medication adjustments, or if the sleep 
history is suspicious for a sleep disorder, polysomnographic evaluation of 
sleep should be undertaken. If no treatable sleep disorder is identified, 
treatment with modafinil or other wake-promoting agents can be 
considered. The dose range of modafinil in these studies was 200 mg/d to 
400 mg/d. 
 Insomnia; can be treated by having the patient adhere to a 
consistent sleep schedule, attempt to avoid daytime napping, and abstain 
from alcohol, caffeine, tobacco, and other stimulants in the evening 
hours. A review of all current medications is warranted to identify those 
that might be causing insomnia, such as bronchodilators, stimulants, 
antidepressants, and weight-loss medications. If night time awakenings 
are related to parkinsonian motor symptoms, a bedtime dose of a DA, 
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carbidopa / levodopa CR,  or carbidopa / levodopa-entacapone (Stalevo) 
may be helpful. A carbidopa / levodopa IR dose may provide relief if the 
patient awakens at night and cannot get back to sleep because 
medications have worn off. If necessary, injections of subcutaneous 
apomorphine may be considered. If insomnia is related to nocturia, 
anticholinergic medications such as tolterodine at bedtime may be helpful 
to reduce bladder spasms. Depression and anxiety should be treated. 
Some patients may require the use of hypnotics, such as zolpidem, or 
trazadone to treat insomnia. 
 VIVID DREAMS AND HALLUCINATIONS; Vivid dreams are 
often a precursor to frank hallucinations. Hallucinations are usually 
triggered by dopaminergic medications in patients with underlying 
dementia. In such patients, it is usually helpful to reduce or eliminate 
DAs and minor PD medications, including amantadine and perhaps 
anticholinergics and MAO-B inhibitors. Hallucinations commonly 
respond to the addition of an atypical neuroleptic such as quetiapine or 
clozapine at bedtime. Quetiapine is usually the medication of choice 
because unlike clozapine, blood monitoring is not required. 
 REM BEHAVIOUR DISORDER: RBD is characterized by loss of 
atonia during REM sleep when dreaming occurs. This leads to an ‘‘acting 
out of dreams,’’ including sleep talking, shouting, and intense, sometimes 
violent, movements. Patients may inadvertently injure their bed partners 
by punching or choking them. RBD has been reported in 25% to 50% of 
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patients with PD and can precede the onset of PD by several years. 
Clonazepam can be used in dosages of 0.5 mg to 2.0 mg at bedtime to 
treat RBD. 
 RESTLESS LEGS SYNDROME : Restless legs syndrome occurs 
in approximately 20% of patients with PD.DAs, including ropinirole and 
pramipexole, may be used to treat. 
 SLEEP APNEA: Obstructive sleep apnea occurs in about 20% of 
patients with PD and is defined by intermittently absent or reduced 
airflow during sleep despite respiratory effort. Treatment usually consists 
of wearing an airflow mask (continuous positive airway pressure). 
 FATIGUE; Fatigue is characterized by a feeling of lack of energy. 
Some patients appear to have fatigue related to depression and improve 
with antidepressant treatment. Others may improve with initiation of 
antiparkinsonian medications. Treatments for fatigue include modafinil 
and other stimulants.  
 ORTHOSTATIC HYPOTENSION; Treatment consists of 
adequate hydration with eight or more glasses of fluid each day, the 
liberal addition of salt to the diet (up to 150 mEq to 250 mEq), and the 
use of mineralocorticoids, such as fludrocortisone, to increase 
intravascular volume. The initial dose of fludrocortisone is 0.1 mg once 
or twice a day, which can be increased to 0.3 mg to 0.6 mg per day if 
needed. Midodrine is a peripherally acting alpha1agonist that produces 
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arteriole and venous capacitance vessel vasoconstriction. The initial 
dosage of midodrine is 2.5 mg twice a day(bid) or tid with a maintenance 
doe of up to 30 mg/d to 40 mg/d in divided doses. 
 CONSTIPATION; PD have delayed colonic transit time compared 
with non-PD controls as well as decreased basal anal sphincter pressures 
and hypercontractile external sphincter response. The disease process 
itself may affect the enteric nervous system as Lewy bodies have been 
found in the myenteric plexus of the colon and in the dorsal group of the 
nucleus intermediolateralis of the third sacral segment of the spinal cord. 
A paradoxical contraction of the striated sphincter muscles during 
defecation called anismus may occur in patients with PD and is 
considered to be a focal dystonia.  
 Treatment of constipation in PD starts with dietary change to 
include more fruits, vegetables, and bran products. Medications that 
inhibit gastric motility and promote gastrointestinal dryness, such as 
anticholinergics, should be discontinued as feasible. If this is ineffective, 
medical management includes polyethyleneglycol, an osmotic agent that 
softens the stool and increases the frequency of bowel movements by 
causing water to be retained in the stool. The recommended dose is 17 g 
or one heaping tablespoon of powder per day in 8 ounces of liquid. Stool 
softeners can often help to relieve constipation in PD as well.  
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 One controlled study found that tegaserod, a prokinetic agent, 
provides modest improvement in constipation. Two open-label studies 
found that mosapride, a selective 5-HT4 agonist, improves constipation, 
but controlled studies are lacking. Lactulose may be needed for patients 
with refractory constipation. For cases of anismus, botulinum toxin 
injections may be considered(30 units of botulinum toxin into two sites 
on the puborectalis muscle). 
 DYSPHAGIA; Patients with PD have increased oropharyngeal 
transit time, and Lewy bodies have been found in the myenteric plexus in 
the esophagus in dysphagic PD patients. Non–dopamine related 
abnormalities in the pedunculopontine nucleus or related structures in the 
medulla may also cause swallowing difficulties. optimal treatment with 
levodopa can improve swallowing, although some patients may need to 
eliminate hard foods from the diet. Liquids may need to be thickened, and 
patients should swallow sitting upright. 
 URINARY INCONTINENCE : Patients with PD may experience 
urinary incontinence. Detrusor hyperreflexia can result in urinary 
frequency, urgency, and nocturia, and dopamine deficiency has been 
implicated as a cause for urinary incontinence in PD. Patients who report 
urinary incontinence should undergo a urological evaluation, including 
cystometric studies, to exclude other causes of urinary symptoms. 
Treatment options include a reduction in fluids in the evening to reduce 
nocturia and anticholinergic medication such as tolterodine tartrate, 
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oxybutyninchloride, or propantheline bromide. Another option is the 
intranasal administration of desmopressin at bedtime to decrease urine 
production overnight. 
 DROOLING; Drooling in PD is caused by saliva pooling in the 
mouth secondary to swallowing difficulties rather than an increased 
production of saliva. Siallorhea can lead to aspiration. Treatment includes 
anticholinergic medications, such as glycopyrrolate. For some patients, 
increased dopaminergic therapy may reduce drooling by improving 
swallowing. 
 SEXUAL DYSFUNCTION: Sexual dysfunction is a complex 
problem in PD and can manifest as difficulty achieving or maintaining 
erection, loss of sexual interest, or occasionally hypersexuality from 
dopaminergic medications. Sexual dysfunction affects both men and 
women with PD. Reports of sexual dysfunction warrant an evaluation by 
a urologist and cessation of medications such as propranolol and other 
antihypertensives that can contribute to the condition. Depression as a 
possible cause of sexual dysfunction must also be addressed. Sildenafil, a 
potent inhibitor of phosphodiesterase type 5, may be useful in treating 
erectile dysfunction. 
 DEPRESSION: Depression is estimated to affect as many as 50% 
of patients with PD and is more common than in age-matched non-PD 
controls. Depression in PD is associated with dysphoria and sadness, and 
less by self-blame and guilt. It may affect patients prior to the onset of 
motor symptoms and may prove to be a preclinical marker of the disease. 
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 The exact cause of depression in PD is unknown. Antidepressants, 
including tricyclics and SSRIs, have been found to improve depression in 
patients with PD, and the DA pramipexole may also have antidepressant 
efficacy. 
 DEMENTIA; Dementia probably affects close to 40% of patients 
with PD and usually emerges later in the course of the disease. Dementia 
in PD is associated with longer disease duration and older age at onset 
and is a risk factor for nursing home placement. Patients with dementia 
have short-term memory deficits but may also have difficulty with verbal 
fluency and personality and behavioral changes. Rivastigmine,  
a cholinesterase inhibitor, is now approved for use in treating dementia in 
PD. In a study of donepezil, at dosages of 5 mg/d to 10 mg/d, 
improvements occurred in the Mini-Mental State Examination and 
Clinical Global Impression scale compared with placebo. Galantamine 
may also improve cognitive dysfunction in PD. 
 PSYCHOSIS; Occurs in 30% of patients. Unfortunately, many 
medications that are used to treat motor dysfunction in PD, including 
amantadine, DAs, and to a lesser extent anticholinergics, levodopa, 
COMT inhibitors, and MAO-B inhibitors, can exacerbate psychosis and 
may need to be discontinued or reduced if psychosis occurs. Quetiapine 
and clozapine have less parkinsonian side effects than other atypical or 
classical antipsychotics and are effective in treating psychosis symptoms, 
usually at relatively low doses(12.5 mg/d to 150 mg/d for quetiapine and 
12.5 mg/d to 75 mg/d for clozapine). 
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OBSERVATION & RESULTS: 
 This study included 100 patients with Idiopathic Parkinson’s 
Disease. 
AGE DISTRBUTION: 
 The number of patients in the  
 age group between 50 -60 years  -  47 
 age group between 60-70 years    -  41 
 age group > 70 years                      - 12 
 
 
 
  
 
 
 
SEX  DISTRIBUTION: 
 There were 75 males and 25 females. 
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DURATION OF DISEASE: 
 The number of patients with the 
 duration of the disease from  0-5  years -   73 
 duration of the disease from 5-10 years  -  21  
 duration of the disease > 10 years          -  6 
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STAGE OF DISEASE: 
 Based on the Hoehn and Yahr Staging;   
number of patients in Stage   1 -   24  
number of patients in Stage   1.5 -  7 
number of patients in Stage    2   -  34 
number of patients in Stage   2.5  - 8 
number of patients in Stage   3     - 23 
number of patients in Stage   4    -   4 
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PREVALENCE OF NON-MOTOR SYMPTOMS IN THE STUDY 
COHORT: The prevalence of NMS were; 
Drooling-37% 
Disturbances in taste and smell-27% 
Swallowing difficulty-24% 
Constipation-50% 
Urgency-47% 
Nocturia-58% 
Dizziness-34% 
Pains-28% 
Dreams-23% 
Insomnia-35% 
Sleepiness-20% 
Memory-33% 
Anxiety-22% 
Depression-34% 
Hallucination-15% 
Sexual Dysfunction-14% 
Falls-24% 
Restless leg syndrome-14% 
Sweating-40% 
Weight loss-16% 
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 The prevalence of NMS across the various stages of Idiopathic 
Parkinson’s disease  are ;  
The number of NMS in Stages 1 and 1.5 were less than 5(range of 2-3) 
The number of  NMS in Stages 2 and 2.5 were in the range of 5 and 7. 
The number of NMS in Stages 3 and 4 were between 9 and 12. 
 The patients in Hoehn and Yahr Stages 1 to 1.5 had duration of 
disease ranging between 6 months and 2 years. Those in Stages 2 and 2.5 
had duration of disease between 2 and 5 years.Patients in Stages 3 and 4 
had duration of disease ranging between 5 and 15 years. 
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DISCUSSION 
 
 Chaudhari K R,Martinez Martin P,Schapira AHV, et al (49) from 
the Unit of Neuro Epidemiology of Carlos Institute of Health, Madrid, 
Spain have done an International Multicentre Pilot Study of the first 
comprehensive self completed non motor symptoms questionnaire for 
Parkinson Disease. They have studied the prevalence of NMS in 545 
patients using the NMS Quest. The results were Dribbling - 40%, 
Disturbances in taste / smell-29%, swallow- 28%,  constipation-
50%,urgency - 53%, nocturia - 60%, pains - 27%, memory-43%, 
hallucination-20%, depression - 45%, anxiety - 42%, sexual  dysfunction-
30%, dizziness-35%, falls - 25%, sleepiness - 29%, insomnia-43%, 
dreams - 34%, RLS - 39%, sweating - 15%, weight  loss - 15%. 
 Our study has shown higher prevalence of NMS like Nocturia 
(58%),  urgency (47%)  and  constipation(50%).This compares with 
Chaudhari et al which has also shown higher prevalence of these 
symptoms namely Nocturia (60%),urgency (53%) and constipation 
(50%). The  next  prevalent NMS were Insomnia (35%), Depression 
(34%) memory (33%),  dreams (23%), anxiety (22%), sleepiness (20%) 
and hallucinations (15%).  These were less compared to Chaudhari et al 
which has documented a higher prevalence of the same, namely Insomnia 
(43%), memory (43%), Depression (45%) dreams (34%), anxiety (42%), 
sleepiness (29%), hallucinations (20%). 
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 Dizziness was reported in 34%,swallowing difficulty in 24%,falls 
in 24% which has almost the same as reported by Chaudhari et al. Sexual 
Dysfunction was reported in14% patients as against 30% by Chaudhari et 
al. Sweating was prevalent in 40% as against 15% reported by Chaudhari 
et al.RLS was reported in 14% which was 39% in Chaudhari at al. Pain 
was prevalent in 28%,and weight loss in 16% which is same when 
compared with Chaudhari et al. 
 The most prevalent NMS were Autonomic Symptoms namely 
Nocturia urgency, constipation, sweating, dizziness and drooling. This 
was followed by Neuropsychiatric symptoms like memory disturbances, 
depression, anxiety and hallucinations and sleep disturbances which 
include insomnia, sleepiness and dreams. Pains and weight loss were also 
prevalent. Diplopia, delusions, bowel and bladder incontinence were 
reported in a small percentage of patients. 
 The prevalence of NMS increased with the severity and duration of 
the disease. The number of NMS ranged between 2 to 3 in stages 1 and 
1.5, increased to 5 to 7 in stages 2 and 2.5 and ranged between 9 to 12 in 
stages 3 and 4.The number of NMS were less when the duration of the 
disease was less than 2 years and increased with the duration of the 
disease. It was maximum reported when the duration of the disease was 
more than 5 years.  
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 In the Indian context, Prevalence of NMS in PD has been carried 
out at NIMS, Hyderabad, Andhra Pradesh, India. Here the patients had 
NMS scores between 6 to 20. The most common symptoms identified 
were dribbling of saliva, swallowing difficulty, urinary urgency, sexual 
dysfunction, unexplained pains,  anxiety, dreams, insomnia, sweating, 
memory disturbances and falls. Alteration in taste and smell, bowel and 
urinary incontinence, change in weight and hallucinations were seen in 
fewer patients. 
 In another study carried out at the Comprehensive Care Centre For 
Movement Disorders, Sree Chitra Tirunal Institute for Medical Sciences 
and Technology, Tiruvananthapuram, Kerala, NMS was assessed by the 
NMS Scale (9 domains) in 100 consecutive PD patients. The Mood / 
cognition domain was most frequently involved (84.2%), while the 
cardiovascular domain was the least affected (22.4%). Four of the 
domains namely, cardiovascular, perceptual problems, hallucinations, 
gastrointestinal and urinary showed significant correlation with the 
duration of the disease and severity of PD. There was a significant 
correlation between the overall severity of NMS and duration of disease 
and severity of PD. 
 Dagmar Verban etal (50) from the Department of Neurology, 
Leiden University Medical centre, The Netherlands 2007 has 
characterised these non motor domains in patients of the Profiling 
Parkinson’s Disease (PROPARK) cohort and describes their relation with 
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other domains of the disease as well as their impact on disability and 
quality of life. Of the domains evaluated olfaction is the only domain that 
seemed unrelated to any of the other impairment domains. All other 
nonmotor symptoms were related to symptoms of other domains. The 
strongest relation was found between night time sleep problems and 
depressive symptoms and between psychotic and autonomic symptoms. 
 The relation found between the different impairment domains may 
emerge through different causes. First two domains may be related 
because of a shared underlying mechanism that is inherent to the disease 
or may be induced by medication or by a combination of both. Second a 
relation between impairment domains may emerge because different 
brain regions are simultaneously affected by the disease process. The 
pathological staging system of Braak, in which the upper brainstem, 
midbrain and limbic system become involved as the disease progresses, 
may explain the co-occurrence of features from two different domains. Of 
the nonmotor domains in PD depressive symptoms and autonomic 
dysfunction were the most important contributors to HRQoL. Our study 
has also demonstrated relation between insomnia and depression. 
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CONCLUSION 
 
(1)  Nonmotor symptoms are prevalent across all stages of Parkinson’s 
Disease. 
(2)  The most prevalent ones were Autonomic which includes 
Constipation, Nocturia, Urgency and sweating. This was followed 
by insomnia, depression and memory disturbances. Dizziness, 
Drooling, Falls and unexplained pains were also significantly 
reported. 
(3)  The number of NMS increased as the disease severity progressed. 
The number of NMS in stages 1 and 1.5 were the least. It increased 
through stages 2 and 2.5 and were highest reported in stages 3  
and 4. 
(4)  The number of NMS also correlated with the duration of the 
disease. The number of NMS were least when the duration was less 
than 2 years, increasing as the duration increased and maximum 
reported when duration was more than 5 years. 
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1 56 M 5 49 3 Y y y y y y y y y y y y
2 66 M 2 30 1.5   y   y       y   y                     
3 59 M 1 27 1   y       y               y             
4 65 M 2 23 2 y     y y y                         y   
5 69 F 4 42 1.5       y y y y                         y 
6 60 F 9 52 3 y   y y y       y   y y   y     y   y   
7 62 M 4 41 2   y     y y   y         y     y         
8 60 M 2 25 1.5               y       y   y             
9 53 M 2 52 3 y y   y y y   y y           y   y   y   
10 64 F 6 54 3 y   y y y y y     y y   y       y       
11 54 M 2 29 1   y       y               y             
12 51 F 2 30 1       y y y                             
13 65 M 4 44 2 y y y y     y
14 50 F 7 49 3 y y y y y     y y y y y y
15 52 F 4 52 2       y   y       y       y         y   
16 46 M 2 51 3 y y y y y y y         y   y     y   y   
17 52 F 8 44 2       y   y     y   y                   
18 51 M 3 33 2 y       y y           y   y             
19 56 M 8 53 3 y     y y y y   y y   y   y     y   y   
20 63 M 1 24 1   y       y                         y   
21 72 M 3 31 2       y y y y           y           y   
22 55 M 2 46 2 y             y y y y                   
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23 59 M 2 42 2   y       y       y y     y             
24 52 M 1 33 1       y                   y             
25 55 M 1.5 27 1   y         y y                         
26 60 F 3 27 1           y       y       y             
27 67 M 5 49 2 y   y y                             y   
28 55 M 3 48 2       y y y       y                 y   
29 61 M 5 55 3 y     y y y y   y     y     y   y       
30 66 M 3 31 2 y     y   y                             
31 58 M 1 26 1   y   y       y                         
32 68 M 5 36 3 y y     y y   y y y y           y   y   
33 60 M 6 45 3     y y y y y   y     y     y   y   y   
34 73 M 3 52 3 y y y y y y y         y   y   y     y y 
35 72 M 1 32 2       y   y y             y             
36 78 F 2 37 2 y       y y           y                 
37 55 F 1 29 1   y           y                         
38 62 M 1.5 32 1   y                   y   y             
39 78 M 1.5 63 2       y   y               y       y y   
40 60 M 1 22 1   y   y       y                         
41 55 M 3 43 2.5 y   y y     y         y                 
42 62 M 2 42 2 y     y     y   y                       
43 68 M 15 68 3 y y y y y         y   y   y y   y   y   
44 62 M 9 50 2.5 y y   y         y         y         y   
45 56 F 2 36 1.5   y     y         y       y   y         
46 60 M 4 60 2   y   y y y y y           y       y y   
47 70 M 3 79 3 y y   y y y   y y     y   y y   y       
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48 77 M 8 81 3 y   y y y y   y y   y       y   y   y y 
49 58 M 4 61 2.5 y   y   y y   y y                   y   
50 62 M 8 61 3 y       y y   y   y y y   y   y     y   
51 60 M 7 48 2       y   y y         y   y         y y 
52 58 M 2 32 1   y   y     y         y             y   
53 68 M 3 33 2 y         y y   y                       
54 52 M 1 34 1           y y y y         y             
55 62 M 2 32 1     y y y y       y                   y 
56 57 M 5 70 3 y     y y y     y y   y y y     y y y   
57 70 M 1 54 2           y y       y   y               
58 54 M 1.5 34 1         y y     y                       
59 55 M 1 51 2       y y y   y               y         
60 65 M 15 67 2.5 y     y           y y     y         y   
61 65 F 13 109 4 y   y       y y y y   y y y     y   y   
62 52 F 2 59 2     y     y   y y y                 y   
63 69 M 10 78 3 y   y   y y y   y           y   y     y 
64 58 M 1 24 1   y                       y             
65 60 M 2 40 2     y             y y y                 
66 63 M 1.5 30 1.5           y y y   y                     
67 70 M 8 89 3 y       y y           y y y     y y y y 
68 62 F 5 36 2   y y         y   y   y                 
69 55 M 4 52 2.5       y y y                 y     y     
70 53 M 2 26 1       y                   y   y         
71 60 F 9 80 3 y   y y y y y     y y y         y   y y 
72 70 M 4 38 2         y               y         y y y 
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73 56 M 3 40 2             y y           y         y y 
74 58 F 12 122 4 y   y y   y y     y y   y y     y   y   
75 54 M 1 24 1                         y y   y         
76 66 M 2.5 40 2         y y     y                 y     
77 52 F 1 28 1               y         y             y 
78 71 M 6 92 3     y y y   y   y   y y     y   y       
79 55 M 4 64 2.5       y   y       y y         y         
80 57 F 2 30 1.5   y         y y                       y 
81 64 M 2 42 2 y   y                   y         y     
82 58 M 5 102 3         y   y   y     y y   y y y   y y 
83 76 M 3 48 2       y           y   y           y     
84 52 F 1 28 1         y     y               y         
85 65 M 0.5 26 1   y                               y     
86 59 M 2.5 44 2         y y       y     y   y           
87 60 M 4 98 3         y y y   y     y     y   y   y y 
88 62 M 14 126 4 y   y y y y     y     y         y   y   
89 64 M 1 40 2         y         y       y             
90 67 F 3 48 2.5 y   y       y       y               y y 
91 54 F 1 22 1           y   y         y             y 
92 70 F 8 110 3 y     y y   y     y   y y   y   y   y y 
93 52 M 2.5 32 2             y           y     y       y 
94 55 M 1 24 1   y     y                 y             
95 60 M 2 46 2       y y             y   y       y     
96 56 F 3 50 2.5     y     y       y y y             y   
97 58 M 3 48 2           y y                 y   y   y 
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98 53 M 1.5 30 1   y           y         y               
99 57 F 2 36 1.5             y y   y y                 y 
100 64 M 12 106 4       y y y     y y y y y y     y y     
       
                 Y – yes             
   
